Cite
HARVARD Citation
Zhou, C. et al. (n.d.). 511PAURA17 study of osimertinib in Asia-Pacific patients (pts) with EGFR T790M-positive advanced non-small cell lung cancer (NSCLC): Updated phase II results including overall survival (OS). Annals of oncology. p. . [Online].